Dr. Paweletz is head of the Translational Research Laboratory (TRL) of the Belfer Institute for Applied Cancer Science at Dana Faber Cancer Institute in Cambridge, Massachusetts. He joined from Merck & Co., Inc., where he most recently served as principal scientist, externalization lead, and proteomics site lead for the Department of Molecular Biomarkers at the Merck Research Laboratory in Boston.
Deborah is a Senior Scientist at Tessa Therapeutics where her work focuses on developing and qualifying molecular assays for characterization or lot release of Tessa's cell therapy products targeting a wide range of cancer indications.
Dr Edmund Ang is currently a Principal Scientist with MERCK BioReliance® Biosafety Testing Services providing scientific and technical support and thought leadership on biologics safety testing to biopharma in the Asia Pacific region
Rapidly developed Droplet Digital PCR (ddPCR) complements qPCR for COVID-19 testing, offering greater sensitivity. The Biodesix® SARS-CoV-2 ddPCR™ Test is FDA EUA pending and available in CLIA labs.
Dr. Qian Liang is currently a R&D lead of POCT department at Jiangsu Bioperfectus Technologies Co., Ltd – a Chinese STAR market listed firm focusing on molecular diagnosis technologies.
Dr. Toru Uchiyama, MD, Chief, Department of Human Genetics, National Center for Child Health and Development, Japan
Plasma ctDNA monitoring via ddPCR shows promise as an early predictor of tumor response in NSCLC patients treated with immunotherapy, offering a less-invasive approach for assessing KRAS/BRAF mutations.
David Dobnik has been in close contacts with companies for gene therapy, helping in process development with characterizations of viral vectors. He also conducted training workshops for digital PCR and executed a digital PCR tech transfer to pharmaceutical company. He continues to work in the field of gene therapy in cooperation with virus vector manufacturing companies.
Dr. Ren has rich experience in PCR assay development & validation, and in testing operation management. In the recent years, he is focused on the QC analytics for AAV Production.
Pete joined Biogen in 2012, and for 7 years he was a member of the Bioassay and Gene Therapy group within the Analytical Development department (PO&T). There he supported the characterization and development of clinical stage protein biologic and AAV vector‑based gene therapy programs.
As part of the gene therapy revolution at bluebird bio, Russell is blending his expertise in biochemistry and molecular virology with QC and drug development experience to recode the way we develop genetic medicine. At bluebird, he has supported efforts ranging from late-stage vector platform analytics to the development of novel assays for the next generation of CAR‑T therapies.